Analgesics market to hit expected to hit $79 billion by 2028

16 August 2018
marketreportbig

According to analysts at Future Market Insights (FMI), the global analgesics market is likely to be worth $79 billion by the end of 2028, indicating a compound annual growth rate of 5% over the next 10 years.

Abuse-deterrent opioids are speculated to be a significant growth market following the ongoing opioid addiction crisis in North America, as well as non-opiod painkillers to complement governmental policies that disincentivize opioid prescription. In developing markets, opioids are expected to remain a valuable investment due to the relative scarcity of analgesics generally.

Additionally, FMI reports that leading analgesics manufacturers are developing non-opioid painkillers with innovative extended release formulations, enhancing the ability for cutting-edge analgesics to treat chronic pain.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical